About this Presentation
Hypophosphataemia can occur in up to 47% of patients following ferric carboxymaltose (FCM) infusions for iron deficiency. However, it is rarely seen following ferric derisomaltose (FDI) or ferrumoxytol infusions. Iron infusion-induced hypophosphataemia is caused by an increase in the phosphaturic hormone, fibroblast growth factor-23 (FGF-23) and can be severe and long-lasting, leading to osteomalacia and bone pain. This presentation provides an updated on IV iron induced hypophosphatemia and osteomalacia and how to prevent and treat this condition in patients.
About the Expert
Prof Peter Ebeling AO
Professor Peter Ebeling AO is Head of the Department of Medicine in the School of Clinical Sciences at Monash Health. He was also inaugural Director of the Australian Institute of Musculoskeletal Science (AIMSS).
Professor Ebeling was Associate Editor of Journal of Bone and Mineral Research from 2008-2012. He currently serves on the Editorial Board of Osteoporosis International and is Editor of Clinical Endocrinology (Oxf) and is Editor-in-Chief of JBMR Plus. He is Medical Director of Osteoporosis Australia; Board Member, International Osteoporosis Foundation; Past-President, Endocrine Society of Australia; Past-President of the Australian and New Zealand Bone and Mineral Society; and Councillor, American Society of Bone and Mineral Research.
